Overview
- Research tools company focused on products and services to advance drug development
- Key technology allows for multiplexed spatial profiling of tissue and cell samples
- Acquired by Bruker (Nasdaq: BRKR) in 2020
Highlights
- Founded and raised initial round of funding without technology - value based solely on strength of leadership team
- Acquired Zellkraftwerk in Germany and Core Diagnostics in the Bay Area to expand portfolio in 2019
- Built international team of 70+ employees
- Acquired less than 4 years after
raising initial capital and launching operations
